Avandia to be to Studied for Prevention of Type 2 Diabetes

Jan 1, 2001

SmithKline Beecham announced in a November 8, 2000 press release that its type 2 drug Avandia (rosiglitazone) will be the only diabetes drug studied in a first-of-its kind, multi-national, 4,000-person study to determine the impact of intensive drug therapy on preventing type 2 diabetes.

Led by Doctors Hertzel Gerstein and Salim Yusuf of McMaster University in Canada, this study, known as the DREAM trial (Diabetes Reduction Approaches with Ramipril and Rosiglitazone Medications), follows last year's HOPE study (Heart Outcomes Prevention Evaluation), which concluded that using the ACE inhibitor Ramipril improved cardio-vascular outcomes.

DREAM is the first study to extensively evaluate the ability of intensive therapy with Avandia and/or Ramipril to prevent diabetes.

Avandia targets insulin resistance and treats this underlying cause of type 2 diabetes.

"Therefore, testing the hypothesis that Avandia should prevent or delay the progression of type 2 diabetes is a logical next step," says David M. Stout, president-North America, SmithKline Beecham Phar-maceuticals.

"Clearly the best way to prevent the serious health consequence of diabetes is to prevent it from occurring in the first place," says Jeff Probstfield, MD, professor of medicine and epidemiology at University of Washington Health Sciences Center and U.S. DREAM investigator.

The DREAM study will be funded by SmithKline Beecham Pharmaceuticals, King Pharmaceuticals and Aventis Pharma Canada.

Click Here To View Or Post Comments

Categories: Diabetes, Diabetes, Insulin, Medications Research, Type 2 Issues, Type 2 Medications


Take the Diabetes Health Pump Survey
See What's Inside
Read this FREE issue now
For healthcare professionals only

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter

Latest
Popular
Top Rated
Print | Email | Share | Comments (0)

You May Also Be Interested In...


Click Here To View Or Post Comments

Comments 0 comments - Jan 1, 2001

©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.